Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2023-10-23 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) announcement from TiumBio, detailing the completion of a private placement of convertible bonds. It specifies the issuance amount, date, and method. This falls under the category of capital and financing updates, specifically related to the issuance of debt instruments (convertible bonds).
2023-10-23 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) issued by TiumBio regarding the issuance of convertible bonds (전환사채권 발행결정). It details the terms of the bond, including interest rates, conversion rights, call/put options, and the list of investors. This type of filing is a standard regulatory disclosure for capital raising activities in the Korean market, which falls under the 'Capital/Financing Update' category.
2023-10-13 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting conditions. Since this document pertains to the issuance of new rights/shares (stock options) and does not fit into specific categories like 'Director's Dealing' (which is for existing shares) or 'Share Issue' (which is for capital changes), it is classified as a general regulatory filing.
2023-10-13 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from a Korean company (TiumBio) regarding the 'Acquisition of Convertible Bonds before Maturity'. It details the specific bond series, the amount acquired, the reason (put option/mutual agreement), and the method of disposal (cancellation). This falls under capital structure and financing updates, specifically related to debt instruments.
2023-08-31 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (반기보고서) for the company 'TiumBio' covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial information, business descriptions, management discussions, and corporate governance details. According to the classification rules, a comprehensive financial report for a period shorter than a full fiscal year (like a semi-annual or quarterly report) that contains actual financial statements and analysis is classified as an Interim / Quarterly Report (IR). H1 2023
2023-08-14 Korean
본점소재지변경
Regulatory Filings Classification · 100% confidence The document is a short regulatory announcement regarding a change in the company's headquarters location (본점소재지변경). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor does it relate to share transactions or management changes. As it is a general corporate regulatory disclosure, it falls under the RNS (Regulatory Filings) category.
2023-08-11 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.